Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 26Gynecologic 12Gastrointestinal 12Tumor-Agnostic 7Genitourinary 7Other solid neoplasm 6CNS 3Breast 3Sarcoma 2Other hematologic neoplasm 2Head & Neck 2NET 1Endocrine 1Dermatologic 1

Conditions

Breast Neoplasms 3Inflammatory Breast Neoplasms 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × nintedanib × Breast × Clear all
NCT01658462 2026-03-16

VAROCE

Centre Oscar Lambret

Phase 2 Completed
51 enrolled
Breast

Breast Neoplasms

NCT02619162 2019-07-23

Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics

Centro Nacional de Investigaciones Oncologicas CARLOS III

Phase 1 Completed
25 enrolled
Breast

Breast Neoplasms

NCT02389764 2019-07-17

Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)

M.D. Anderson Cancer Center

Phase 2 Terminated
10 enrolled 9 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡